Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01813110 · ClinicalTrials.gov registry record · NA

Effects of a Prescription Omega-3 Fatty Acid Concentrate on Induced Inflammation

A NA study, sponsored by Penn State University.

Completed
Registry status
NA
Development phase
21
Enrollment target

NCT01813110: Completed NA study, sponsored by Penn State University.

NCT01813110 is a NA study that has completed, run by Penn State University. The registered enrollment target is 21 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01813110, a NA study, has completed, sponsored by Penn State University.

COMPLETED
Registry status
NA
Development phase
21 participants
Enrollment target

Study Summary

The purpose of this study is to assess whether the marine omega-3 fatty acids can attenuate inflammatory responses to endotoxin challenge.

Primary Outcome

Change in blood levels of CRP at 24 hours post endotoxin administration, after each 8 week intervention

Interventions

  • DRUG Placebo
  • DRUG 4 g prescription omega-3 concentrate

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2014-05
Est. Completion 2015-04
Phase NA
Penn State University

219 total trials

What the finished NCT01813110 record still lists

NCT01813110 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01813110 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01813110 about?

NCT01813110 is a clinical study titled "Effects of a Prescription Omega-3 Fatty Acid Concentrate on Induced Inflammation". The purpose of this study is to assess whether the marine omega-3 fatty acids can attenuate inflammatory responses to endotoxin challenge.

What is the current status of trial NCT01813110?

This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2014-05. Estimated completion is 2015-04.

What interventions are being tested in trial NCT01813110?

The interventions under investigation include: Placebo (DRUG), 4 g prescription omega-3 concentrate (DRUG).

Who is sponsoring clinical trial NCT01813110?

This trial is sponsored by Penn State University, which has 219 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01813110's enrollment target sits among peer trials

21 1762nd of 2000 higher than 233 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02447874 · 21 participants · Phase 1

    Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease

  • NCT03826992 · 21 participants · Phase 1

    Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

  • NCT04107077 · 21 participants · Phase 2

    Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer

  • NCT04158635 · 21 participants · Phase 1

    Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01813110, the US trial registry maintained by the National Library of Medicine. NCT01813110 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.